Could a Parkinson's drug help depressed people feel pleasure again?

NCT ID NCT06075771

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether L-DOPA, a drug used for Parkinson's, can improve anhedonia (loss of interest or pleasure) in people with depression who also have high inflammation. Seventy adults aged 25-55 will receive either L-DOPA or a placebo for 8 weeks. Researchers will measure changes in depression symptoms and brain activity using MRI scans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

L-DOPA (carbidopa levodopa)

What this could lead to

If it works, this could point toward a new treatment for anhedonia (loss of pleasure) in people with depression and high inflammation.

What could go wrong

This is a small, early-phase trial with only 70 people. It may not show a clear benefit, and L-DOPA can cause side effects like nausea or dizziness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Anhedonia Depression depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Emory University Hospital

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••